parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in pituitary stem cells	0.75
chemistry Open Targets	compounds already reach it: sonidegib, taladegib, sonidegib phosphate +7	1.00
trials ClinicalTrials.gov	26 Parkinson's trials, 4 stopped	0.88
literature PubMed	7 Parkinson's papers of 3,765	0.73
pathways Reactome	5 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 11633

receipt 11641: SMO in dopamine neurons, braak

power: full sample -0.28 (p 0.254, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.34 (p 0.173, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.45 (p 0.059, n 18). could be the mix.
skeptic: leave-one-out range -0.40 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.254, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SMO in dopamine neurons.

case closed: nothing better to follow up.

receipt 11640: SMO in astrocytes, braak

power: full sample -0.45 (p 0.059, n 18), 95% CI -0.76 to +0.02. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.48 (p 0.044, n 18). holds up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.41 (p 0.091, n 18). could be the mix.
skeptic: leave-one-out range -0.58 to -0.37, sign flips 0; without severely affected donors -0.45 (p 0.059, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SMO in astrocytes.

case closed: nothing better to follow up.

loading the receipts